T1	Participants 39 80	homozygous familial hypercholesterolaemia
T2	Participants 163 204	Homozygous familial hypercholesterolaemia
T3	Participants 789 862	ten countries in North America, Europe, the Middle East, and South Africa
T4	Participants 864 1213	50 eligible patients (aged â‰¥12 years) with homozygous familial hypercholesterolaemia, on stable lipid-regulating therapy for at least 4 weeks, and not receiving lipoprotein apheresis, were randomly allocated by a computer-generated randomisation sequence in a 2:1 ratio to receive subcutaneous evolocumab 420 mg or placebo every 4 weeks for 12 weeks
T5	Participants 1372 1590	Patients, study personnel, and the funder were masked to treatment and to the efficacy results by the central laboratory not returning LDL cholesterol or any lipid results to the clinical sites after the baseline visit
T6	Participants 1833 2024	Of the 50 eligible patients randomly assigned to the two treatment groups, 49 actually received the study drug and completed the study (16 in the placebo group and 33 in the evolocumab group)
T7	Participants 2176 2309	Treatment-emergent adverse events occurred in ten (63%) of 16 patients in the placebo group and 12 (36%) of 33 in the evolocumab grou
T8	Participants 2461 2722	In patients with homozygous familial hypercholesterolaemia receiving stable background lipid-lowering treatment and not on apheresis, evolocumab 420 mg administered every 4 weeks was well tolerated and significantly reduced LDL cholesterol compared with placebo
